Article of the Week, Suggested by the BPDCN International Registry
Immune Oncology Research Institute shared a post on LinkedIn:
“Article of the Week Suggested by the BPDCN International Registry – Astghik Voskanyan
Clonal evolution and blastic plasmacytoid dendritic cell neoplasm: malignancies of divergent hematopoietic lineages emerging from a common founding clone
BPDCN is a rare and aggressive blood cancer often arising from clonal hematopoiesis (CH). Up to 20% of cases share a clonal origin with myeloid neoplasms like CMML. Differentiating BPDCN from AML with pDC-like features is challenging, but epigenetic profiling has uncovered molecular distinctions. A study documented two cases of BPDCN arising after lymphoid malignancies (T-LBL and ALK-negative ALCL), confirming a common clonal origin and highlighting clonal evolution across multiple cancers.”
Authors: Svenja Denker, Axel Künstner, Julian Schwarting, Hanno M. Witte, Veronica Bernard, Stephanie Stölting, Philipp Lohneis, Kathrin Kusch, Nikolas von Bubnoff, Hartmut Merz, Hauke Busch, Alfred C. Feller and Niklas Gebauer.
Immune Oncology Research Institute (IMMONC), established in 2022, is a non-profit, independent, patient-centered research institute. The mission of IMMONC is to advance the cancer knowledge and care through breakthrough scientific research, to integrate innovative immune-oncology therapies into the clinical practice for different types of cancers, to generate and collect clinical data for the identification of new therapeutic targets, developing predictive models and optimizing patient outcomes, to increase the availability and accessibility of those discoveries for the cancer patients, to create a world-class professional environment, to attract the brightest minds in cancer field and to train the next generation researchers.
Other posts featuring Immune Oncology Research Institute on OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023